In this review, we highlighted the HSP90 chaperone machinery as an interesting target for drug resistant cancer, as well as the importance of nanocarriers to overcome physiological barriers to deliver therapeutics and to improve drug efficacy without increasing side effects. This evidence concerns the gene HSP90AA1 and cancer.